Found: 45
Select item for more details and to access through your institution.
Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long‐acting glucagon analogue HM15136 in overweight and obese patients with co‐morbidities.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 9, p. 2723, doi. 10.1111/dom.15162
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready‐to‐use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2679, doi. 10.1111/dom.14520
- By:
- Publication type:
- Article
Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 3, p. 700, doi. 10.1111/dom.14272
- By:
- Publication type:
- Article
Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 8, p. 1292, doi. 10.1111/dom.14032
- By:
- Publication type:
- Article
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 11, p. 2429, doi. 10.1111/dom.13824
- By:
- Publication type:
- Article
Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK‐1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. 400, doi. 10.1111/dom.13084
- By:
- Publication type:
- Article
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 1, p. 94, doi. 10.1111/dom.13042
- By:
- Publication type:
- Article
<sup>LAPS</sup>Insulin115: A novel ultra-long-acting basal insulin with a unique action profile.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 12, p. 1722, doi. 10.1111/dom.13006
- By:
- Publication type:
- Article
Exploring the insulin secretory properties of the PGD<sub>2</sub>-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients.
- Published in:
- PLoS ONE, 2018, v. 13, n. 12, p. 1, doi. 10.1371/journal.pone.0208998
- By:
- Publication type:
- Article
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01788-6
- By:
- Publication type:
- Article
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
- Published in:
- BMC Pharmacology & Toxicology, 2013, v. 14, n. 1, p. 1, doi. 10.1186/2050-6511-14-26
- By:
- Publication type:
- Article
Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?
- Published in:
- Pharmaceutical Medicine, 2014, v. 28, n. 3, p. 109, doi. 10.1007/s40290-014-0053-7
- By:
- Publication type:
- Article
766-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, and Pharmacokinetics (PK) from Part 1 of a Phase 1b Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HV).
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-766-P
- By:
- Publication type:
- Article
765-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) from Part 2 of a Phase 1b Multiple Ascending Dose (MAD) Study in Patients with Type 2 Diabetes Mellitus (T2DM).
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-765-P
- By:
- Publication type:
- Article
901-P: Evaluation of the Analytical Performance of YSI 2900D Compared with YSI 2300 STAT Plus for Glucose Concentration Measurements.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-901-P
- By:
- Publication type:
- Article
107-LB: Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects (HS).
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-107-LB
- By:
- Publication type:
- Article
106-LB: Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Subjects with T1DM and T2DM.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-106-LB
- By:
- Publication type:
- Article
982-P: A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-982-P
- By:
- Publication type:
- Article
53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-53-OR
- By:
- Publication type:
- Article
1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1023-P
- By:
- Publication type:
- Article
1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1014-P
- By:
- Publication type:
- Article
1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1001-P
- By:
- Publication type:
- Article
Endocrine Homeostasis with Inhibition of Tissue-Specific Cortisone Reductase Activity in Healthy Volunteers and Obese Insulin Resistant Subjects Following Oral INCB13739 11βHSD1 Inhibitor Therapy.
- Published in:
- Diabetes, 2007, v. 56, p. A572
- By:
- Publication type:
- Article
Pharmacokinetics and Pharmacodynamics of Insulin VIAject™ and Regular Human Insulin When Injected Subcutaneously Directly Before a Meal in Patients with Type I Diabetes.
- Published in:
- Diabetes, 2007, v. 56, p. A9
- By:
- Publication type:
- Article
Targeting Hyperglycaemia with Anti-Obesity Drugs: Time for a Paradigm Shift?
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Developing New Drugs for Diabetes and Cardiometabolic Disorders.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2020, v. 105, n. 4, p. e1235, doi. 10.1210/clinem/dgz258
- By:
- Publication type:
- Article
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes.
- Published in:
- PLoS ONE, 2014, v. 9, n. 8, p. 1, doi. 10.1371/journal.pone.0105638
- By:
- Publication type:
- Article
α-Lipoic Acid in NIDDM Patients With Cardiac Autonomic Neuropathy.
- Published in:
- Diabetes Care, 1997, v. 20, n. 12, p. 1918, doi. 10.2337/diacare.20.12.1918a
- By:
- Publication type:
- Article
A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1383, doi. 10.1002/cpt.3225
- By:
- Publication type:
- Article
A Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Insulin Dimer.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 1, p. 125, doi. 10.1002/cpt.2607
- By:
- Publication type:
- Article
Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH.
- Published in:
- Endocrinology, Diabetes & Metabolism, 2022, v. 5, n. 3, p. 1, doi. 10.1002/edm2.335
- By:
- Publication type:
- Article
Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients.
- Published in:
- Endocrinology, Diabetes & Metabolism, 2021, v. 4, n. 2, p. 1, doi. 10.1002/edm2.217
- By:
- Publication type:
- Article
Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action 每日1次给予德谷胰岛素(一种持续作用时间超长的基础胰岛素)治疗后在2-3日内可以达到稳态
- Published in:
- Journal of Diabetes, 2016, v. 8, n. 1, p. 132, doi. 10.1111/1753-0407.12266
- By:
- Publication type:
- Article
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2013, v. 36, n. 10, p. 3169, doi. 10.2337/dc13-0387
- By:
- Publication type:
- Article
Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase.
- Published in:
- Diabetes Care, 2013, v. 36, n. 2, p. 273, doi. 10.2337/dc12-0808
- By:
- Publication type:
- Article
Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects.
- Published in:
- Diabetes Care, 2011, v. 34, n. 12, p. 2496, doi. 10.2337/dc11-0721
- By:
- Publication type:
- Article
Accelerated Insulin Pharmacokinetics and Improved Postprandial Glycemic Control in Patients With Type 1 Diabetes After Coadministration of Prandial Insulins With Hyaluronidase.
- Published in:
- Diabetes Care, 2011, v. 34, n. 3, p. 666, doi. 10.2337/dc10-1892
- By:
- Publication type:
- Article
Availability of Inhaled Insulin Promotes Greater Perceived Acceptance of Insulin Therapy in Patients With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2005, v. 28, n. 2, p. 427, doi. 10.2337/diacare.28.2.427
- By:
- Publication type:
- Article